GenScript Executive and Leadership Team

Patrick Liu, the Acting Chief Executive Officer, ProBio at GenScript, directs the strategic trajectory of the biologics development division. Overseeing complex antibody engineering and viral vector manufacturing, the Acting Chief Executive Officer, ProBio ensures alignment with global pharmaceutical standards. This leadership role involves scaling production capabilities to meet the rigorous demands of gene therapy and vaccine development. By optimizing operational workflows, Patrick Liu directly impacts the efficiency of clinical-stage manufacturing projects. The Acting Chief Executive Officer, ProBio maintains a focus on high-impact innovations, ensuring that the division remains a preferred partner for biotech firms. Through rigorous oversight of technical resources, the Acting Chief Executive Officer, ProBio secures long-term growth for the ProBio unit. Ultimately, Liu drives the expansion of manufacturing capacity to support international drug discovery initiatives, reinforcing the market position of the organization within the competitive life sciences sector.

Phil Zhou, the Chief Financial Officer at GenScript, manages the fiscal health and capital allocation strategies for the entire enterprise. Overseeing financial planning, reporting, and investor relations, the Chief Financial Officer ensures that resource distribution aligns with long-term research and development goals. This leadership role involves monitoring global market trends to mitigate financial risks associated with large-scale peptide and protein engineering projects. By implementing robust budgetary controls, Phil Zhou directly impacts the operational sustainability of the company. The Chief Financial Officer maintains close collaboration with the board to evaluate investment opportunities in emerging biotechnology markets. Through precise financial modeling, the Chief Financial Officer supports the rapid turnaround times required for client-facing services. Ultimately, Zhou secures the necessary capital to fuel ongoing advancements in CRISPR gene editing and mRNA synthesis, ensuring that the organization maintains a strong competitive advantage in the global life sciences landscape.

Luquan Wang, the Executive Director and President at GenScript, architects the overarching corporate governance and operational framework. Overseeing the integration of diverse service lines, the Executive Director and President ensures that molecular cloning and antibody production units function with maximum synergy. This leadership role involves steering the company through complex regulatory environments while maintaining a focus on high-impact scientific outcomes. By fostering a culture of technical excellence, Luquan Wang directly impacts the quality of customizable solutions provided to researchers. The Executive Director and President coordinates with other C-suite leaders to refine the strategic roadmap for international market penetration. Through consistent evaluation of operational performance, the Executive Director and President drives efficiency across all departments. Ultimately, Wang secures the organizational stability required to support critical applications in vaccine development and gene therapy, solidifying the reputation of the company as a trusted partner for scientific development.

Janice Jin, the Division President, , Life Science Group, Genscript (APAC) at GenScript, directs all commercial and operational activities across the Asia-Pacific region. Overseeing the delivery of gene synthesis and protein engineering services, the Division President, , Life Science Group, Genscript (APAC) ensures that regional research institutions receive rapid, high-quality support. This leadership role involves expanding the market footprint by tailoring service offerings to the specific needs of local biotech ecosystems. By optimizing supply chain logistics within the region, Janice Jin directly impacts the speed of project delivery for clients. The Division President, , Life Science Group, Genscript (APAC) maintains strong relationships with key academic and industrial partners to drive regional growth. Through strategic management of local talent and resources, the Division President, , Life Science Group, Genscript (APAC) enhances the overall service capacity. Ultimately, Jin secures a dominant market position for the company, facilitating critical advancements in regional drug discovery and scientific research.

Patrick L., the President, Biosciences Group at GenScript, leads the development and commercialization of the core bioscience product portfolio. Overseeing the innovation pipeline for CRISPR gene editing and mRNA synthesis tools, the President, Biosciences Group ensures that the company remains at the forefront of molecular biology technology. This leadership role involves translating complex scientific requirements into scalable, customizable solutions for global researchers. By managing the product lifecycle from concept to market, Patrick L. directly impacts the revenue growth of the biosciences division. The President, Biosciences Group collaborates with technical teams to refine antibody production processes, ensuring high-impact results for drug discovery applications. Through rigorous market analysis, the President, Biosciences Group identifies emerging trends to guide future research investments. Ultimately, L. secures the technological leadership of the organization, providing the essential tools that empower scientists to achieve breakthroughs in gene therapy and vaccine development across international markets.